# Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

> **NCT01496989** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 75 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-MAG (3,000mcg)
- **BIOLOGICAL:** GENEVAX® IL-12 (100mcg)
- **BIOLOGICAL:** GENEVAX® IL-12 (1000mcg)
- **BIOLOGICAL:** Ad35-GRIN/ENV

## Key facts

- **NCT ID:** NCT01496989
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** —
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2013-09-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496989, "Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01496989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*